Market revenue in 2023 | USD 9.3 million |
Market revenue in 2030 | USD 21.5 million |
Growth rate | 12.7% (CAGR from 2023 to 2030) |
Largest segment | Kits & reagents |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Kits & Reagents, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Lonza Group Ltd, Merck KGaA, Charles River Laboratories International Inc, Asahi Kasei Corp, Sartorius AG, Eurofins Scientific SE, PromoCell GmbH, ATCC, InvivoGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mycoplasma testing market will help companies and investors design strategic landscapes.
Kits & reagents was the largest segment with a revenue share of 58.06% in 2023. Horizon Databook has segmented the Sweden mycoplasma testing market based on instruments, kits & reagents, services covering the revenue growth of each sub-segment from 2018 to 2030.
The country is expected to witness significant growth due to several factors, such as the growing biopharmaceutical industry, advanced infrastructure, & supportive government initiatives. Furthermore, Sweden has a strong R&D focus on scientific innovation and is home to leading academic institutions & research organizations. As of December 2023, Sweden has more than 300 drugs in active development within its pharmaceutical R&D pipeline.
This placed Sweden fifth in Europe for the number of drugs under development, which is a notable achievement, especially considering the economic size of the traditional EU5 countries. When combined with its Nordic neighbors, the region is surpassed only by the UK and Switzerland. In addition, Sweden boasts one of the highest percentages of preclinical-stage drug candidates among its peers.
However, these candidates face higher risks of not progressing to approved drugs for patients. As more drugs progress through development stages, ensuring the purity of cell cultures becomes crucial, necessitating rigorous mycoplasma testing. Innovations in testing methods will likely emerge, offering faster and more cost-effective solutions to meet the growing needs of the pharmaceutical industry.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden mycoplasma testing market , including forecasts for subscribers. This country databook contains high-level insights into Sweden mycoplasma testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account